NO330170B1 - Fremgangsmate for fremstilling av et bioaktivt peptid - Google Patents

Fremgangsmate for fremstilling av et bioaktivt peptid Download PDF

Info

Publication number: NO330170B1
Authority: NO; Norway
Prior art keywords: peptide; peptides; cationic; amino acids; lipophilic
Prior art date: 1999-08-31

Application number

NO20020950A

Other languages

English (en)

Norwegian (no)

Other versions

NO20020950D0 (no

NO20020950L (no

Inventor

John Sigurd Svendsen

Oystein Rekdal

Mari Wikman

Terese Solstad

Nannan Yang

Original Assignee

Lytix Biopharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-31

Filing date

2002-02-27

Publication date

2011-02-28

1999-08-31 Priority claimed from PCT/GB1999/002851 external-priority patent/WO2000012542A2/en

2002-02-27 Application filed by Lytix Biopharma As filed Critical Lytix Biopharma As

2002-02-27 Publication of NO20020950D0 publication Critical patent/NO20020950D0/no

2002-04-25 Publication of NO20020950L publication Critical patent/NO20020950L/no

2011-02-28 Publication of NO330170B1 publication Critical patent/NO330170B1/no

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 250
238000000034 method Methods 0.000 title claims abstract description 35
230000000975 bioactive effect Effects 0.000 title claims abstract description 8
230000008569 process Effects 0.000 title description 5
125000002091 cationic group Chemical group 0.000 claims abstract description 91
150000001413 amino acids Chemical class 0.000 claims abstract description 90
-1 cationic amino acids Chemical class 0.000 claims abstract description 27
238000010348 incorporation Methods 0.000 claims abstract description 7
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 28
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 25
238000004519 manufacturing process Methods 0.000 claims description 8
102000004196 processed proteins & peptides Human genes 0.000 abstract description 122
201000011510 cancer Diseases 0.000 abstract description 6
238000002560 therapeutic procedure Methods 0.000 abstract description 4
238000011282 treatment Methods 0.000 abstract description 4
229940024606 amino acid Drugs 0.000 description 101
235000001014 amino acid Nutrition 0.000 description 98
230000000694 effects Effects 0.000 description 44
210000004027 cell Anatomy 0.000 description 34
CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical group C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 25
230000001225 therapeutic effect Effects 0.000 description 21
101800004361 Lactoferricin-B Proteins 0.000 description 20
230000000259 anti-tumor effect Effects 0.000 description 19
230000001988 toxicity Effects 0.000 description 19
231100000419 toxicity Toxicity 0.000 description 19
241000894006 Bacteria Species 0.000 description 16
230000000844 anti-bacterial effect Effects 0.000 description 16
210000003743 erythrocyte Anatomy 0.000 description 16
230000001965 increasing effect Effects 0.000 description 16
230000015572 biosynthetic process Effects 0.000 description 15
238000003786 synthesis reaction Methods 0.000 description 14
230000000845 anti-microbial effect Effects 0.000 description 12
210000002950 fibroblast Anatomy 0.000 description 12
239000000203 mixture Substances 0.000 description 12
229960003767 alanine Drugs 0.000 description 11
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 10
235000004279 alanine Nutrition 0.000 description 10
230000002949 hemolytic effect Effects 0.000 description 10
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 9
230000004048 modification Effects 0.000 description 9
238000012986 modification Methods 0.000 description 9
125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 9
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 8
238000011049 filling Methods 0.000 description 8
230000002101 lytic effect Effects 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
210000004881 tumor cell Anatomy 0.000 description 8
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
239000004480 active ingredient Substances 0.000 description 7
230000001580 bacterial effect Effects 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
230000001472 cytotoxic effect Effects 0.000 description 7
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 7
239000002953 phosphate buffered saline Substances 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
239000000243 solution Substances 0.000 description 7
238000012360 testing method Methods 0.000 description 7
108700042778 Antimicrobial Peptides Proteins 0.000 description 6
102000044503 Antimicrobial Peptides Human genes 0.000 description 6
125000003118 aryl group Chemical group 0.000 description 6
230000002068 genetic effect Effects 0.000 description 6
125000006239 protecting group Chemical group 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
238000006467 substitution reaction Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
101000798100 Bos taurus Lactotransferrin Proteins 0.000 description 5
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
108060003100 Magainin Proteins 0.000 description 5
125000000539 amino acid group Chemical group 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
229940072440 bovine lactoferrin Drugs 0.000 description 5
210000000170 cell membrane Anatomy 0.000 description 5
238000010276 construction Methods 0.000 description 5
231100000433 cytotoxic Toxicity 0.000 description 5
210000003527 eukaryotic cell Anatomy 0.000 description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
231100000331 toxic Toxicity 0.000 description 5
230000002588 toxic effect Effects 0.000 description 5
KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
125000000217 alkyl group Chemical group 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
239000002246 antineoplastic agent Substances 0.000 description 4
230000003115 biocidal effect Effects 0.000 description 4
JCZLABDVDPYLRZ-AWEZNQCLSA-N biphenylalanine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1C1=CC=CC=C1 JCZLABDVDPYLRZ-AWEZNQCLSA-N 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
230000002209 hydrophobic effect Effects 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
239000002609 medium Substances 0.000 description 4
239000000816 peptidomimetic Substances 0.000 description 4
150000003904 phospholipids Chemical class 0.000 description 4
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
239000004474 valine Substances 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
239000004472 Lysine Substances 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000012634 fragment Substances 0.000 description 3
125000000524 functional group Chemical group 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
231100000053 low toxicity Toxicity 0.000 description 3
239000012528 membrane Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
238000013519 translation Methods 0.000 description 3
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
108010050820 Antimicrobial Cationic Peptides Proteins 0.000 description 2
102000014133 Antimicrobial Cationic Peptides Human genes 0.000 description 2
108010023063 Bacto-peptone Proteins 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
108050004290 Cecropin Proteins 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
206010018910 Haemolysis Diseases 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
108010063045 Lactoferrin Proteins 0.000 description 2
102000010445 Lactoferrin Human genes 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
239000005864 Sulphur Chemical group 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
125000003275 alpha amino acid group Chemical group 0.000 description 2
125000006242 amine protecting group Chemical group 0.000 description 2
150000001412 amines Chemical group 0.000 description 2
125000000129 anionic group Chemical group 0.000 description 2
238000003556 assay Methods 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000003385 bacteriostatic effect Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
230000007423 decrease Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
235000020776 essential amino acid Nutrition 0.000 description 2
239000003797 essential amino acid Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000012010 growth Effects 0.000 description 2
238000005534 hematocrit Methods 0.000 description 2
230000008588 hemolysis Effects 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
229940078795 lactoferrin Drugs 0.000 description 2
235000021242 lactoferrin Nutrition 0.000 description 2
239000008101 lactose Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
238000005457 optimization Methods 0.000 description 2
229960003104 ornithine Drugs 0.000 description 2
239000001301 oxygen Chemical group 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004417 polycarbonate Substances 0.000 description 2
229920000515 polycarbonate Polymers 0.000 description 2
239000003910 polypeptide antibiotic agent Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
150000003573 thiols Chemical class 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
LKRSUSMQXGCKKX-QHCPKHFHSA-N (2S)-2-amino-2,3-ditert-butyl-3-(1H-indol-3-yl)-4,4-dimethylpentanoic acid Chemical compound C(C)(C)(C)C([C@](N)(C(=O)O)C(C)(C)C)(C1=CNC2=CC=CC=C12)C(C)(C)C LKRSUSMQXGCKKX-QHCPKHFHSA-N 0.000 description 1
ZENNTZUZBRESKJ-ZETCQYMHSA-N (2s)-2-(1-benzothiophen-2-ylamino)propanoic acid Chemical compound C1=CC=C2SC(N[C@@H](C)C(O)=O)=CC2=C1 ZENNTZUZBRESKJ-ZETCQYMHSA-N 0.000 description 1
YPJJGMCMOHDOFZ-ZETCQYMHSA-N (2s)-2-(1-benzothiophen-3-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CSC2=C1 YPJJGMCMOHDOFZ-ZETCQYMHSA-N 0.000 description 1
FNQLUUASYSCLNV-AWEZNQCLSA-N (2s)-2-(cyclohexylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC1CCCCC1)C1=CC=C(O)C=C1 FNQLUUASYSCLNV-AWEZNQCLSA-N 0.000 description 1
IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 1
NJVBZNOXROKNRD-HNNXBMFYSA-N (2s)-2-[(2,6-dichlorophenyl)methylamino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NCC=1C(=CC=CC=1Cl)Cl)C1=CC=C(O)C=C1 NJVBZNOXROKNRD-HNNXBMFYSA-N 0.000 description 1
PECGVEGMRUZOML-AWEZNQCLSA-N (2s)-2-amino-3,3-diphenylpropanoic acid Chemical compound C=1C=CC=CC=1C([C@H](N)C(O)=O)C1=CC=CC=C1 PECGVEGMRUZOML-AWEZNQCLSA-N 0.000 description 1
MWHVBFNZTDNYRK-HNNXBMFYSA-N (2s)-2-azaniumyl-3-(7-phenylmethoxy-1h-indol-3-yl)propanoate Chemical compound C1=CC=C2C(C[C@H]([NH3+])C([O-])=O)=CNC2=C1OCC1=CC=CC=C1 MWHVBFNZTDNYRK-HNNXBMFYSA-N 0.000 description 1
ADJZXDVMJPTFKT-JTQLQIEISA-N (2s)-2-azaniumyl-4-(1h-indol-3-yl)butanoate Chemical compound C1=CC=C2C(CC[C@H](N)C(O)=O)=CNC2=C1 ADJZXDVMJPTFKT-JTQLQIEISA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
ZAQXSMCYFQJRCQ-UHFFFAOYSA-N 3-(1-adamantyl)-2-azaniumylpropanoate Chemical compound C1C(C2)CC3CC2CC1(CC(N)C(O)=O)C3 ZAQXSMCYFQJRCQ-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
DRDWXKWUSIKKOB-PJODQICGSA-N Arg-Trp-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(O)=O DRDWXKWUSIKKOB-PJODQICGSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
241001529572 Chaceon affinis Species 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical group C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
108010002069 Defensins Proteins 0.000 description 1
102000000541 Defensins Human genes 0.000 description 1
YCAGGFXSFQFVQL-UHFFFAOYSA-N Endothion Chemical compound COC1=COC(CSP(=O)(OC)OC)=CC1=O YCAGGFXSFQFVQL-UHFFFAOYSA-N 0.000 description 1
241000588697 Enterobacter cloacae Species 0.000 description 1
241000305071 Enterobacterales Species 0.000 description 1
241001360526 Escherichia coli ATCC 25922 Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
108091006975 Iron transporters Proteins 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
101800004761 Magainin-2 Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108010036176 Melitten Proteins 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
101800004819 PGLa Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
AUJWXNGCAQWLEI-KBPBESRZSA-N Phe-Lys-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O AUJWXNGCAQWLEI-KBPBESRZSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
241000269368 Xenopus laevis Species 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
239000012911 assay medium Substances 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
239000003659 bee venom Substances 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
229940096529 carboxypolymethylene Drugs 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000004590 computer program Methods 0.000 description 1
238000005094 computer simulation Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940059082 douche Drugs 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
238000006266 etherification reaction Methods 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000013265 extended release Methods 0.000 description 1
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
235000004554 glutamine Nutrition 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
229910052736 halogen Chemical group 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
150000002367 halogens Chemical group 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000009215 host defense mechanism Effects 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229950008325 levothyroxine Drugs 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
MGIUUAHJVPPFEV-ABXDCCGRSA-N magainin ii Chemical compound C([C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O)C1=CC=CC=C1 MGIUUAHJVPPFEV-ABXDCCGRSA-N 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
231100001225 mammalian toxicity Toxicity 0.000 description 1
VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
108091005601 modified peptides Proteins 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
210000004882 non-tumor cell Anatomy 0.000 description 1
231100000065 noncytotoxic Toxicity 0.000 description 1
150000007523 nucleic acids Chemical group 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
238000005192 partition Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
230000035699 permeability Effects 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
239000002574 poison Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229940075065 polyvinyl acetate Drugs 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000012987 post-synthetic modification Methods 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
244000062645 predators Species 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
239000003380 propellant Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000001846 repelling effect Effects 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
235000004400 serine Nutrition 0.000 description 1
UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
239000004208 shellac Substances 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000005556 structure-activity relationship Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000011885 synergistic combination Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
235000008521 threonine Nutrition 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
238000006257 total synthesis reaction Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000002476 tumorcidal effect Effects 0.000 description 1
239000002435 venom Substances 0.000 description 1
231100000611 venom Toxicity 0.000 description 1
210000001048 venom Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Toxicology (AREA)
Zoology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Semiconductor Lasers (AREA)

NO20020950A 1999-08-31 2002-02-27 Fremgangsmate for fremstilling av et bioaktivt peptid NO330170B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/GB1999/002851 WO2000012542A2 (en)	1998-08-28	1999-08-31	Cytotoxic lactoferrin derivatives modified by bulky or lipophilic moieties
GBGB0005702.6A GB0005702D0 (en)	2000-03-09	2000-03-09	Method
PCT/GB2000/003378 WO2001019852A2 (en)	1999-08-31	2000-08-31	Methods of peptide preparation

Publications (3)

Publication Number	Publication Date
NO20020950D0 NO20020950D0 (no)	2002-02-27
NO20020950L NO20020950L (no)	2002-04-25
NO330170B1 true NO330170B1 (no)	2011-02-28

Family

ID=9887296

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20020950A NO330170B1 (no)	1999-08-31	2002-02-27	Fremgangsmate for fremstilling av et bioaktivt peptid

Country Status (14)

Country	Link
US (1)	US7393824B1 (da)
EP (1)	EP1259536B1 (da)
JP (1)	JP4902919B2 (da)
AT (1)	ATE422502T1 (da)
AU (1)	AU781243B2 (da)
CA (1)	CA2382544A1 (da)
CY (1)	CY1109450T1 (da)
DE (1)	DE60041556D1 (da)
DK (1)	DK1259536T3 (da)
ES (1)	ES2322228T3 (da)
GB (1)	GB0005702D0 (da)
NO (1)	NO330170B1 (da)
PT (1)	PT1259536E (da)
WO (1)	WO2001019852A2 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030220258A1 (en)	2001-12-21	2003-11-27	Robbert Benner	Treatment of ischemic events
US8680059B2 (en)	1998-05-20	2014-03-25	Biotempt B.V.	Oligopeptide acetate and formulations thereof
US8283315B2 (en)	1998-08-28	2012-10-09	Lytix Biopharma As	Inhibition of tumour growth
GB0005703D0 (en)	2000-03-09	2000-05-03	Alpharma As	Compounds
NO20031818D0 (no) *	2003-04-23	2003-04-23	Uni I Tromsoe	Fremgangsmåte av bioaktiv peptid forberedelse
JP4846799B2 (ja) *	2005-07-05	2011-12-28	バイオテンプトベー．フェー．	腫瘍の治療
EP1864692A1 (en)	2006-06-07	2007-12-12	Biotempt B.V.	Use of peptides for the control of radiation injury
KR101863136B1 (ko)	2008-01-24	2018-05-31	에스퍼란스 파마슈티컬스, 인코포레이티드	용해 도메인 융합 구성물 및 이를 제조하고 사용하는 방법
GB0821616D0 (en)	2008-11-26	2008-12-31	Lytix Biopharma As	Compounds
WO2013124436A1 (en) *	2012-02-23	2013-08-29	University Of East London	Synthetic anti-microbial peptides with a minority of cationic and a majority hydrophobic side chains
IL238323B2 (en)	2012-10-30	2023-11-01	Esperance Pharmaceuticals Inc	Antibody/drug conjugates and methods of use
GB201401877D0 (en)	2014-02-04	2014-03-19	Univ Tromsoe	Peptides
JPWO2016056665A1 (ja) *	2014-10-08	2017-08-10	学校法人慶應義塾	白血球の細胞外トラップ形成の阻害剤
GB201810635D0 (en) *	2018-06-28	2018-08-15	Norut Northern Res Institute As	Peptides and cancer treatment
CN111704652B (zh) *	2020-06-02	2022-04-22	昆明医科大学	一种抗光损伤皮肤保护活性多肽om-gl15及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5547939A (en) *	1991-06-14	1996-08-20	The Regents Of The University Of California	Broad spectrum antimicrobial compounds and methods of use
CA2217572A1 (en) *	1995-04-05	1996-10-10	The Picower Institute For Medical Research	Agents for binding to advanced glycosylation endproducts, and methods of their use
WO1998006425A1 (en)	1996-08-12	1998-02-19	A+ Science Invest Ab	Treatment and prevention of infections, inflammations and/or tumours with lactoferrin and/or lactoferricin
US6333311B1 (en) *	1997-02-03	2001-12-25	Pharming	Useful properties of human lactoferrin and variants thereof
GB9818938D0 (en) *	1998-08-28	1998-10-21	Alpharma As	Bioactive peptides

2000
- 2000-03-09 GB GBGB0005702.6A patent/GB0005702D0/en not_active Ceased
- 2000-08-31 AU AU68587/00A patent/AU781243B2/en not_active Ceased
- 2000-08-31 EP EP00956720A patent/EP1259536B1/en not_active Expired - Lifetime
- 2000-08-31 PT PT00956720T patent/PT1259536E/pt unknown
- 2000-08-31 JP JP2001523629A patent/JP4902919B2/ja not_active Expired - Fee Related
- 2000-08-31 ES ES00956720T patent/ES2322228T3/es not_active Expired - Lifetime
- 2000-08-31 US US10/069,613 patent/US7393824B1/en not_active Expired - Fee Related
- 2000-08-31 AT AT00956720T patent/ATE422502T1/de active
- 2000-08-31 DK DK00956720T patent/DK1259536T3/da active
- 2000-08-31 CA CA002382544A patent/CA2382544A1/en not_active Abandoned
- 2000-08-31 DE DE60041556T patent/DE60041556D1/de not_active Expired - Lifetime
- 2000-08-31 WO PCT/GB2000/003378 patent/WO2001019852A2/en not_active Ceased
2002
- 2002-02-27 NO NO20020950A patent/NO330170B1/no not_active IP Right Cessation
2009
- 2009-05-08 CY CY20091100495T patent/CY1109450T1/el unknown

Also Published As

Publication number	Publication date
NO20020950D0 (no)	2002-02-27
DE60041556D1 (de)	2009-03-26
US7393824B1 (en)	2008-07-01
WO2001019852A3 (en)	2002-09-12
EP1259536B1 (en)	2009-02-11
WO2001019852A8 (en)	2004-04-15
WO2001019852A2 (en)	2001-03-22
AU6858700A (en)	2001-04-17
CY1109450T1 (el)	2014-08-13
DK1259536T3 (da)	2009-06-08
PT1259536E (pt)	2009-05-14
JP4902919B2 (ja)	2012-03-21
NO20020950L (no)	2002-04-25
ES2322228T3 (es)	2009-06-18
EP1259536A2 (en)	2002-11-27
GB0005702D0 (en)	2000-05-03
CA2382544A1 (en)	2001-03-22
JP2003516931A (ja)	2003-05-20
AU781243B2 (en)	2005-05-12
ATE422502T1 (de)	2009-02-15

Legal Events

Date	Code	Title	Description
2012-03-26	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
CA2341037C (en)	2013-11-05	Bioactive peptides
US9115169B2 (en)	2015-08-25	Method of treating tumors
NO330170B1 (no)	2011-02-28	Fremgangsmate for fremstilling av et bioaktivt peptid
AU2001237616A1 (en)	2001-11-29	Antimicrobial compounds and formulations
EP3096616A2 (en)	2016-11-30	Dermaseptin-type and piscidin-type antimicrobial peptides
US9109048B2 (en)	2015-08-18	Inhibition of tumor growth
US20200071357A1 (en)	2020-03-05	Antimicrobial peptides
WO2004094462A2 (en)	2004-11-04	Methods of peptide preparation
Douglas	2013	Marine Flatfish-Derived Bioactive Peptides: From the